Imagine a world where the risk of HIV transmission could be significantly reduced with just two treatments a year. Sounds groundbreaking, right? Well, that’s exactly what’s on the horizon with the recent approval of Yeytuo (lenacapavir) by the TGA for HIV Pre-Exposure Prophylaxis (PrEP). But here’s where it gets controversial: while this twice-yearly treatment promises to revolutionize HIV prevention for adults and adolescents aged 16 and older (weighing at least 35kg), it also raises questions about accessibility and long-term adherence compared to daily PrEP options. And this is the part most people miss—lenacapavir isn’t just a PrEP game-changer; it’s also available as Sunleca, a treatment for HIV when combined with other antiretrovirals. This dual role positions lenacapavir as a versatile tool in the fight against HIV, but it also sparks debate: Is a twice-yearly regimen truly feasible for widespread use? Or could it inadvertently lead to complacency in prevention efforts? Let’s dive deeper into this development, which was first shared with subscribers in Pharmacy Daily on January 14, 2026. To explore the full newsletter, check out the embedded issue below or CLICK HERE to download the edition directly.
In other health news, the landscape of public health is shifting in unexpected ways. Recreational drug overdoses are on the rise, with clinical toxicologists in Queensland reporting a startling increase over the past decade. Methamphetamine intoxication has now surpassed paracetamol as the leading cause of toxicological emergencies—a trend that demands urgent attention. Meanwhile, smartphone apps are proving to be surprisingly effective tools for smoking cessation, with studies showing they can be up to three times more successful than minimal or no support. Could this be the future of addiction treatment? And in a move that’s sure to impact millions, Health Minister Mark Butler has pledged to include Wegovy (semaglutide) on the PBS, following the PBAC’s recommendation. This decision could transform access to weight management treatments, but it also raises questions about cost-effectiveness and long-term health outcomes.
As we navigate these advancements, one thing is clear: the intersection of innovation and public health is more dynamic than ever. What’s your take? Do you think twice-yearly PrEP treatments like lenacapavir will become the new standard, or are daily regimens still the way to go? Share your thoughts in the comments—let’s spark a conversation that could shape the future of HIV prevention and beyond.
